NCT06367465View on ClinicalTrials.gov

Feasibility and Acceptability of HCV Treatment in Pregnancy

RecruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Hepatitis CPregnancy Complications
Interventions
DRUG

Glecaprevir-pibrentasvir

Glecaprevir-pibrentasvir 100 mg / 40 mg 3 tab orally (PO) once daily for 56 days.

Trial Locations (2)

63110

RECRUITING

Barnes Jewish Hospital, St Louis

RECRUITING

Washington Univeristy, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER